N-[2-ethoxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide | 2495-96-7

• 物质功能分类: 生物化工 - 糖类化合物 - 单糖
• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-[2-ethoxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
• CAS: 2495-96-7
• 化学式: C₁₀H₁₉NO₆
• 分子量: 249.26
• InChiKey: KRABAWXNIPSDEF-UHFFFAOYSA-N

物化性质

• 熔点：
  178-180℃
• 沸点：
  526℃
• 密度：
  1.32
• 闪点：
  272℃

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  108
• 氢给体数：
  4
• 氢受体数：
  6

安全信息

• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312+P330,P302+P352,P304+P340+P312,P305+P351+P338,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C，干燥

文献信息

• [EN] CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS ANTISENS CONJUGUÉS ET LEUR UTILISATION
  申请人：ISIS PHARMACEUTICALS INC

  公开号：WO2014179620A1

  公开（公告）日：2014-11-06

  Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.

  本文提供了具有共轭基团的寡聚化合物。在某些实施例中，这些寡聚化合物与N-乙酰半乳糖结合。
• [EN] POLYNUCLEOTIDE CONSTRUCTS<br/>[FR] CONSTRUCTIONS POLYNUCLÉOTIDIQUES
  申请人：SOLSTICE BIOLOGICS LTD

  公开号：WO2018035380A1

  公开（公告）日：2018-02-22

  Disclosed are polynucleotide constructs having a strand linked to a moiety carrying one or more auxiliary moieties. Also disclosed are polynucleotide constructs interrupted with a sugar analogue, and polynucleotide constructs with stereochemical^ enriched phosphorothioates. The polynucleotide constructs may be provided as hybridized polynucleotide constructs. Also featured are methods of delivery a polynucleotide construct to a cell and methods of reducing the expression of a protein in a cell by contacting the cell with the disclosed polynucleotide construct or hybridized polynucleotide construct.

  揭示了具有与携带一个或多个辅助基团的基团相连的多核苷酸构造。还披露了被糖类似物中断的多核苷酸构造，以及具有立体化学富集的磷酸硫酸酯的多核苷酸构造。这些多核苷酸构造可以作为杂交多核苷酸构造提供。还包括将多核苷酸构造传递给细胞的方法，以及通过将细胞与披露的多核苷酸构造或杂交多核苷酸构造接触来减少细胞中蛋白质表达的方法。
• NOVEL TLR4 INHIBITORS FOR THE TREATMENT OF HUMAN INFECTIOUS AND INFLAMMATORY DISORDERS
  申请人：System of Higher Education University of Pittsburgh - of the Commonwealth

  公开号：US20130281395A1

  公开（公告）日：2013-10-24

  The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.

  本发明涉及通过给予新发现具有TLR4抑制活性的各种化合物来治疗感染性、炎症性和创伤后疾病的方法。除了治疗方法外，本发明还提供了包括所述化合物在内的药物组合物，以及适当的药物载体。由于TLR4是促炎性LPS信号级联中最上游的受体，本发明的治疗方法可以通过抑制或拮抗TLR4的作用来避免与其他细胞因子抑制剂相关的缺陷，这些细胞因子抑制剂作用于信号通路中较下游的位置，因此起到了不太特异（也许是非关键）的作用。
• METHOD OF PREPARING GLYCOPEPTIDES
  申请人：Wong Chi-Huey

  公开号：US20110060121A1

  公开（公告）日：2011-03-10

  A method is provided for the synthesis of glycopeptides using a sugar assisted ligation strategy, wherein an N-terminal peptide portion in the form of a thioester is coupled with a C-terminal peptide portion bearing a carbohydrate moiety comprising a thiol group.

  提供了一种使用糖辅助连接策略合成糖肽的方法，其中将以硫酯形式的N-末端肽部分与带有含硫基的碳末端肽部分结合，后者具有糖基团。
• MODIFIED OLIGONUCLEOTIDES AND COMPOUND THAT CAN BE USED FOR SYNTHESIZING SAME
  申请人：Guangzhou Ribobio Co., Ltd.

  公开号：EP3677588A1

  公开（公告）日：2020-07-08

  The present invention falls within the field of biomedical technology, and in particular relates to modified oligonucleotides and a compound that can be used for synthesizing same and a method for modifying oligonucleotides. The present invention also relates to the use of the modified oligonucleotides for preventing and/or treating diseases associated with the liver in a subject.

  本发明属于生物医学技术领域，尤其涉及修饰的寡核苷酸和可用于合成修饰的寡核苷酸的化合物以及修饰寡核苷酸的方法。本发明还涉及使用经修饰的寡核苷酸预防和/或治疗受试者与肝脏有关的疾病。